BioCardia (BCDA) Revenue & Revenue Breakdown
BioCardia Revenue Highlights
Latest Revenue (Y)
$477.00K
Latest Revenue (Q)
$55.00K
Main Segment (Y)
License
Main Geography (Y)
License
BioCardia Revenue by Period
BioCardia Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $477.00K | -64.72% |
2022-12-31 | $1.35M | 33.20% |
2021-12-31 | $1.01M | 600.00% |
2020-12-31 | $145.00K | -79.58% |
2019-12-31 | $710.00K | 13.60% |
2018-12-31 | $625.00K | 30.48% |
2017-12-31 | $479.00K | -16.84% |
2016-12-31 | $576.00K | 11.41% |
2015-12-31 | $517.00K | 21.08% |
2014-12-31 | $427.00K | 59.33% |
2013-12-31 | $268.00K | 332.26% |
2012-12-31 | $62.00K | 416.67% |
2011-12-31 | $12.00K | 100.00% |
2010-12-31 | - | -100.00% |
2009-12-31 | $1.87M | 47.40% |
2008-12-31 | $1.27M | 100.00% |
2007-06-30 | - | 100.00% |
2006-06-30 | - | 100.00% |
2005-06-30 | - | -100.00% |
2004-06-30 | $3.76M | -7.82% |
2003-06-30 | $4.08M | 3.06% |
2002-06-30 | $3.96M | 2.35% |
2001-06-30 | $3.87M | -3.06% |
2000-06-30 | $3.99M | -5.05% |
1999-06-30 | $4.20M | 10.53% |
1998-06-30 | $3.80M | 11.76% |
1997-06-30 | $3.40M | 8.01% |
1996-06-30 | $3.15M | - |
BioCardia Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-03-31 | $55.00K | 323.08% |
2023-12-31 | $13.00K | -96.36% |
2023-09-30 | $357.00K | 730.23% |
2023-06-30 | $43.00K | -32.81% |
2023-03-31 | $64.00K | -39.62% |
2022-12-31 | $106.00K | -50.00% |
2022-09-30 | $212.00K | -78.23% |
2022-06-30 | $974.00K | 1523.33% |
2022-03-31 | $60.00K | -24.05% |
2021-12-31 | $79.00K | -90.38% |
2021-09-30 | $821.00K | 1089.86% |
2021-06-30 | $69.00K | 50.00% |
2021-03-31 | $46.00K | - |
2020-12-31 | $46.00K | 35.29% |
2020-09-30 | $34.00K | 25.93% |
2020-06-30 | $27.00K | -28.95% |
2020-03-31 | $38.00K | -82.33% |
2019-12-31 | $215.00K | 10.82% |
2019-09-30 | $194.00K | 125.58% |
2019-06-30 | $86.00K | -60.19% |
2019-03-31 | $216.00K | 109.71% |
2018-12-31 | $103.00K | 22.62% |
2018-09-30 | $84.00K | -64.85% |
2018-06-30 | $239.00K | 20.10% |
2018-03-31 | $199.00K | 99.00% |
2017-12-31 | $100.00K | -23.08% |
2017-09-30 | $130.00K | 16.07% |
2017-06-30 | $112.00K | -18.25% |
2017-03-31 | $137.00K | -102.63% |
2016-12-31 | $-5.21M | -194.82% |
2016-09-30 | $5.50M | 3773.24% |
2016-06-30 | $142.00K | -4.70% |
2016-03-31 | $149.00K | 10.37% |
2015-12-31 | $135.00K | 11.57% |
2015-09-30 | $121.00K | -3.20% |
2015-06-30 | $125.00K | -8.09% |
2015-03-31 | $136.00K | 6.25% |
2014-12-31 | $128.00K | 33.33% |
2014-09-30 | $96.00K | -8.57% |
2014-06-30 | $105.00K | 7.14% |
2014-03-31 | $98.00K | 8.89% |
2013-12-31 | $90.00K | 26.76% |
2013-09-30 | $71.00K | 2.90% |
2013-06-30 | $69.00K | 81.58% |
2013-03-31 | $38.00K | 153.33% |
2012-12-31 | $15.00K | -21.05% |
2012-09-30 | $19.00K | 11.76% |
2012-06-30 | $17.00K | 54.55% |
2012-03-31 | $11.00K | -8.33% |
2011-12-31 | $12.00K | 100.00% |
2011-09-30 | - | 100.00% |
2011-06-30 | - | 100.00% |
2011-03-31 | - | -100.00% |
2010-12-31 | $-2.75M | -456.68% |
2010-09-30 | $771.00K | -28.41% |
2010-06-30 | $1.08M | 19.40% |
2010-03-31 | $902.00K | 62.52% |
2009-12-31 | $555.00K | 27.29% |
2009-09-30 | $436.00K | -2.24% |
2009-06-30 | $446.00K | 3.24% |
2009-03-31 | $432.00K | 28.57% |
2008-12-31 | $336.00K | -18.25% |
2008-09-30 | $411.00K | 100.00% |
2008-06-30 | - | 100.00% |
2008-03-31 | - | - |
BioCardia Revenue Breakdown
BioCardia Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 20 | Dec 19 |
---|---|---|
Service | $183.00K | $191.00K |
License | $500.00K | $500.00K |
BioCardia Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 20 | Dec 19 |
---|---|---|
License | $500.00K | $500.00K |
Service | $183.00K | $191.00K |
BioCardia Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
ADAG | Adagene | $18.11M | $833.34K |
BCDA | BioCardia | $477.00K | $55.00K |
ABVC | ABVC BioPharma | $152.43K | $117.14K |
ANEB | Anebulo Pharmaceuticals | - | - |
RZLT | Rezolute | - | - |
FBRX | Forte Biosciences | - | - |
ANTX | AN2 Therapeutics | - | - |
AVTE | Aerovate Therapeutics | - | - |
ERAS | Erasca | - | - |
ACRV | Acrivon Therapeutics | - | - |
MLYS | Mineralys Therapeutics | - | - |
PTIX | Protagenic Therapeutics | - | - |
INDP | Indaptus Therapeutics | - | - |
KTTA | Pasithea Therapeutics | - | - |
BCDA Revenue FAQ
What is BioCardia’s yearly revenue?
BioCardia's yearly revenue for 2023 was $477K, representing a decrease of -64.72% compared to 2022. The company's yearly revenue for 2022 was $1.35M, representing an increase of 33.20% compared to 2021. BCDA's yearly revenue for 2021 was $1.02M, representing an increase of 600.00% compared to 2020.
What is BioCardia’s quarterly revenue?
BioCardia's quarterly revenue for Q1 2024 was $55K, a 323.08% increase from the previous quarter (Q4 2023), and a -14.06% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $13K, a -96.36% decrease from the previous quarter (Q3 2023), and a -87.74% decrease year-over-year (Q4 2022). BCDA's quarterly revenue for Q3 2023 was $357K, a 730.23% increase from the previous quarter (Q2 2023), and a 68.40% increase year-over-year (Q3 2022).
What is BioCardia’s revenue growth rate?
BioCardia's revenue growth rate for the last 3 years (2021-2023) was -53.00%, and for the last 5 years (2019-2023) was -32.82%.
What are BioCardia’s revenue streams?
BioCardia's revenue streams in c 20 are Service, and License. Service generated $183K in revenue, accounting 26.79% of the company's total revenue, down -4.19% year-over-year. License generated $500K in revenue, accounting 73.21% of the company's total revenue
What is BioCardia’s main source of revenue?
For the fiscal year ending Dec 20, the largest source of revenue of BioCardia was License. This segment made a revenue of $500K, representing 73.21% of the company's total revenue.